A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

NCT03535194 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1484

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Mirikizumab
DRUG: Placebo
DRUG: Secukinumab

Sponsor

Eli Lilly and Company